Skip to contentB
BioMarin Pharmaceutical Inc
B
BMRNBioMarin Pharmaceutical Inc Q4 2022 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$537.54M$537.54Mderived+19.5% vs Q4 2021 Net Income-$249.00K-$249.00KderivedN/M vs Q4 2021 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
BioMarin Pharmaceutical Inc · CIK 1048477 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$13,088,000N/M Operating Cash Flowderived$6,786,000−39.3% Free Cash Flowderived-$28,902,000N/M Margins · derivedOperating margin-2.4%+12.2 pt vs Q4 2021
Net margin-0.0%+12.8 pt vs Q4 2021
ended Dec 31, 2022 · filed Feb 27, 2023 · 58 d after period end